West Pharmaceutical Services, Inc. (WST)
Here's Why West Pharmaceutical (WST) Is a Great 'Buy the Bottom' Stock Now
West Pharmaceutical (WST) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Time To Buy The Dip In West Pharmaceutical Stock?
West Pharmaceutical Services (WST) stock should be included in your watchlist. Here's why – it is currently operating within the support zone ($224.83 – $248.49), prices from which it has previously bounced significantly.
WST Launches Synchrony S1 Prefillable Syringe at Pharmapack
West Pharmaceutical debuts the Synchrony S1 prefillable syringe at Pharmapack 2026, enhancing biologics, vaccines and home-care support.
All You Need to Know About West Pharmaceutical (WST) Rating Upgrade to Strong Buy
West Pharmaceutical (WST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
After Plunging 9.7% in 4 Weeks, Here's Why the Trend Might Reverse for West Pharmaceutical (WST)
The heavy selling pressure might have exhausted for West Pharmaceutical (WST) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Reasons to Add West Pharmaceutical Stock to Your Portfolio Now
WST is riding on surging GLP-1 demand and HVP expansion. Yet, pricing pressure, tariff risks and contract manufacturing headwinds cloud the near-term outlook.
Wall Street Analysts See a 26.42% Upside in West Pharmaceutical (WST): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 26.4% in West Pharmaceutical (WST). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Reasons to Retain West Pharmaceutical Stock in Your Portfolio for Now
WST leans on strong HVP demand, rising GLP-1 exposure and Annex 1 tailwinds, even as pricing and device margins weigh on near-term performance.
West Pharmaceutical Services, Inc. (WST) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
West Pharmaceutical Services, Inc. (WST) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
West Pharmaceutical: Back To Growth
West Pharmaceutical Services is rated a buy, supported by strong Q3 results, raised guidance, and a resilient long-term growth thesis. WST's focus on high-value proprietary elastomer components and secular industry drivers, like GLP-1 demand, underpins robust margin and revenue growth. Risks include questionable capital allocation, recent insider selling during buybacks, and potential disruption from oral drug alternatives.
West Pharmaceutical Services, Inc. (WST) Presents at Stephens Annual Investment Conference 2025 Transcript
West Pharmaceutical Services, Inc. ( WST ) Stephens Annual Investment Conference 2025 November 20, 2025 12:00 PM EST Company Participants Robert McMahon - Senior VP & CFO Shane Campbell - SVP & Chief Proprietary Segment Officer John Sweeney - Head of Investor Relations Conference Call Participants Steven Etoch - Stephens Inc., Research Division Presentation Steven Etoch Stephens Inc., Research Division Welcome to day 3 of Stephens 2025 Investment Conference here at Nashville. I'm Mac Etoch, the Life Science Tools and Pharma Services Analyst.
West Pharmaceutical Services, Inc. (WST) Presents at Jefferies London Healthcare Conference 2025 Transcript
West Pharmaceutical Services, Inc. ( WST ) Jefferies London Healthcare Conference 2025 November 18, 2025 5:00 AM EST Company Participants Robert McMahon - Senior VP & CFO Conference Call Participants David Windley - Jefferies LLC, Research Division Presentation David Windley Jefferies LLC, Research Division Good morning. I'm Dave Windley with Jefferies Healthcare Equity Research.
